A Systematic Review of Effects of Vitamin E on the Cardiovascular System

Sunil Shah, Yasir Shiekh, Jannel A. Lawrence, Mohammad Alam, Saru Kunwar, Domonick K. Gordon

Abstract

Vitamin E is a fat-soluble vitamin and an antioxidant that prevents the peroxidation of lipid in vitro. The antioxidant role of vitamin E in preventing adverse cardiovascular outcomes is controversial as some studies support it, while others reject it. Therefore, this review aims to determine whether there is an association between vitamin E and cardiovascular diseases (CVDs). An electronic search was done to find out relevant articles. Papers were shortlisted after the initial title and abstract screen. A full-text study was done, and inclusion and exclusion criteria were applied before the quality assessment of each paper was done. Only high-quality papers were selected for analysis. Full-text articles of the last ten years were included, while non-English articles, gray literature, and animal studies were excluded. The majority of the papers, including 75% of the total population in this review, suggested no role of vitamin E in preventing CVD and CVD mortality. Some studies also suggested that a high level of vitamin E can be associated with adverse cardiovascular outcomes. Thus, one should be prudent about taking vitamin E supplementation for cardiovascular risk prevention.

Categories: Cardiology, Internal Medicine, Preventive Medicine
Keywords: vitamin e, antioxidants, cvd, cardiovascular risks, alpha tocopherol

Introduction And Background

With the increase in advancement in medicine and the health care delivery system, the major cause of morbidity and mortality of the human population is progressively shifting from infectious diseases to non-communicable diseases. Among various important non-communicable diseases, cardiovascular diseases (CVDs) are the major causes of morbidity and mortality. The total deaths due to CVD in 2016 were nearly one-third of all deaths worldwide [1]. In 2017, CVD led to over 330 million years of life lost and 35.6 million years of life lived with disability worldwide [2,3]. The total number of deaths due to CVD in 2017 was over 17 million, and more than 23 million deaths are expected to occur in 2030 across the globe if this rate continues [4].

Vitamin E, one of the fat-soluble vitamins and antioxidants, prevents lipid peroxidation in vitro [5]. Lipid peroxidation is an important initial event in atherosclerosis development and progression, which plays a vital role in developing CVDs [6]. Vitamin E has eight isomers, among which alpha-tocopherol is one of the important forms [5]. Alpha-tocopherol acts as an antioxidant by supplying hydrogen atoms to other radicals that convert the radicals into non-radical products and convert themselves into tocopheroxyl radicals. Tocopheroxyl radical reacts with self or other radicals to form inactive products, thus, breaking the chain of lipid peroxidation reaction.

Some examples of antioxidants are vitamin C, vitamin A, carotenoids, and selenium. Approximately 28%-30% of U.S. (United States of America) adults use supplements that contain various antioxidants [6]. Alpha-tocopherol increases significantly with vitamin E intake and has been postulated to be associated with better cardiovascular health due to antioxidant and anti-atherogenic properties in several studies [7-9].

Some studies have shown the positive effect of vitamin E supplementation against CVD [7-9], while some studies have failed to show its protective role, and few studies have shown possible harmful health effects [10,11]. If there is a significant positive effect of vitamin E on CVDs, supplementation can be done in daily foods to improve the overall cardiac health of the population. However, finding no relation between vitamin E and CVDs would help decrease the unnecessary intake of vitamin E supplementation and possibly prevent its adverse health effect, if there is any. Dietary intake of fruits and vegetables (a rich source of alpha-tocopherol and other antioxidants) is supposed to predict better general health and cardiovascular outcome; however, the role of vitamin E in preventing people from CVD might be due to the combination of various factors.
antioxidants and nutrients contained in food. In this systematic review, we attempt to determine if there is any significant association of vitamin E with CVD and CVD mortality.

**Review**

**Methods**

**Search Strategy and Selection of Studies**

We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) as a reporting guideline for this review article. PubMed Central and Medline were used as two databases, and study selection was done by two reviewers independently from February 28 to March 8, 2021. Regular keywords used to collect studies were "Vitamin E AND Cardiovascular Disease," "Vitamin E AND CVD," "Tocopherols AND Cardiovascular disease," and "Tocopherols AND CVD." MeSH keywords used were ("Vitamin E"[Mesh]) AND "Cardiovascular Diseases"[Mesh]. Only articles that were published in the last 10 years were collected. Initially, studies were selected according to the title’s relevance, followed by abstract review using inclusion and exclusion criteria.

Furthermore, duplicates were removed and two assessors independently reviewed full texts, and the final number of studies was determined after two assessors did quality assessment checks. Quality assessment tools used were; Cochrane Bias Assessment Tool for randomized control trial, Amstar 2 Checklist for systemic review, and Newcastle-Ottawa Quality Assessment Scale for observational studies. Only high-quality studies determined by a score of greater than seven and a low risk of bias during the quality assessment were included. The regular keywords used during data search and the total number of articles for each keyword are shown in Table 1.

| Regular keywords                                      | Database used | Number of papers |
|-------------------------------------------------------|---------------|------------------|
| Vitamin E AND Cardiovascular Disease                  | PubMed        | 266              |
| Vitamin E AND CVD                                     | PubMed        | 42               |
| Tocopherols AND Cardiovascular disease                | PubMed        | 108              |
| Tocopherols AND CVD                                   | PubMed        | 17               |

**TABLE 1: Regular Keywords Used for Data Search**

CVD: Cardiovascular Disease

The MeSH keywords used during data search and the total number of articles for each keyword are shown in Table 2.

| MeSH Keywords                                         | Database used | Number of Papers |
|-------------------------------------------------------|---------------|------------------|
| ("Vitamin E"[Mesh]) AND "Cardiovascular Diseases"[Mesh]| PubMed        | 134              |

**TABLE 2: MeSH Keywords Used for Data Search**

**Criteria for Study Selection**

Inclusion criteria: (1) All publications in the last 10 years (from January 2011 to January 2021). (2) Articles in the English language. (3) Study population aged >18 years. (4) All types of articles from any country.

Exclusion criteria: (1) All publications older than 10 years (before January 2011). (2) Articles not in the English language. (3) Gray literature. (4) Study population aged <18 years.

**Results**

**Search Results**

The electronic database PubMed yielded 567 articles in the initial screening. Two hundred seventy-six
articles remained after the removal of duplicates. After screening the title and abstract, 212 unrelated articles were removed, leaving 64 articles for full-text evaluation. Following a full-text study and applying inclusion and exclusion criteria, 38 articles remained that underwent quality assessment.

Study Quality and Characteristics

Out of 38 studies, 25 studies were considered high-quality papers for analysis after quality assessment. Among 25 studies, three were cross-sectional studies, five were case-control studies, 11 were cohort studies, and six were randomized control trials.

Figure 1 summarizes the data search strategy and selection process.

Figure 1: PRISMA Flow Diagram Showing Data Extraction Process

Only high-quality papers were included in the study. The randomized control trial was assessed by Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2). Only randomized trials with a low risk of bias were included in the study. The quality assessment tools used for cross-sectional [12-14], cohort [15-25], and case-control studies [26-30] were the Newcastle-Ottawa Quality Assessment Tool for cross-sectional, cohort, and case-control studies, respectively. A score of greater than or equal to seven stars during the individual quality assessment, as shown in Table 3, was included in the study.
### Newcastle-Ottawa Quality Assessment

#### Newcastle-Ottawa Quality Assessment of Cross-sectional Studies

| Studies               | Selection (max. 5 stars) | Comparability (max. 2 stars) | Outcome (max. 3 stars) | Total Score (max. 10) |
|-----------------------|--------------------------|------------------------------|------------------------|-----------------------|
| Minotti et al. [12]  | 3                        | 2                            | 3                      | 8                     |
| Kuwabara et al. [13] | 4                        | 2                            | 3                      | 9                     |
| Yildiran et al. [14] | 3                        | 2                            | 3                      | 8                     |

#### Newcastle-Ottawa Quality Assessment of Cohort Studies

| Studies               | Selection (max. 4 stars) | Comparability (max. 2 stars) | Outcome (max. 3 stars) | Total Score (max. 9) |
|-----------------------|--------------------------|------------------------------|------------------------|-----------------------|
| Prentice et al. [15]  | 3                        | 2                            | 2                      | 7                     |
| Huang et al. [16]     | 3                        | 2                            | 3                      | 8                     |
| Lee et al. [17]       | 4                        | 2                            | 3                      | 9                     |
| Eshak et al. [18]     | 4                        | 2                            | 3                      | 9                     |
| Zhao et al. [19]      | 4                        | 2                            | 3                      | 9                     |
| Stepaniak et al. [20] | 4                        | 2                            | 2                      | 8                     |
| Cangemi et al. [21]   | 3                        | 2                            | 2                      | 7                     |
| Wannamethe et al. [22]| 4                        | 2                            | 3                      | 9                     |
| Espe et al. [23]      | 3                        | 2                            | 3                      | 8                     |
| Goyal et al. [24]     | 3                        | 2                            | 3                      | 8                     |
| Ferro et al. [25]     | 3                        | 2                            | 2                      | 7                     |

#### Newcastle-Ottawa Quality Assessment of Case-control Studies

| Studies               | Selection (max. 4 stars) | Comparability (max. 2 stars) | Outcome (max. 3 stars) | Total Score (max. 9) |
|-----------------------|--------------------------|------------------------------|------------------------|-----------------------|
| Llopis-González et al. [26] | 4                       | 2                            | 2                      | 8                     |
| Godala et al. [27]    | 2                        | 2                            | 3                      | 7                     |
| Xu et al. [28]        | 2                        | 2                            | 3                      | 7                     |
| Naidoo et al. [29]    | 4                        | 2                            | 2                      | 8                     |
| Nagao [30]            | 4                        | 2                            | 2                      | 8                     |

### TABLE 3: Newcastle-Ottawa Quality Assessment of Cross-sectional, Cohort and Case-control Studies

max. = maximum

---

#### Actual Result

The total population included in this study was 360,840, among which 63.54% were male and 36.46% were female. Three studies were done in the U.S., and three were from China. Italy and Japan also contributed three studies each, while two studies were done in Australia. The remaining ten articles were obtained from ten individual countries. Two studies included only women, and four included only the male population. Both males and females were included in the remaining articles. The cardiovascular conditions assessed in this review were overall cardiovascular outcome and CVD mortality, hypertension and blood pressure variation, vascular endothelial function, heart failure, myocardial infarction, coronary artery diseases, recurrence of atrial fibrillation, ischemic stroke, and low-density lipoprotein peroxidation. Two studies included cardiovascular outcomes in type 2 diabetes mellitus patients, and two studies included cardiovascular outcomes in end-stage renal disease patients.

#### Discussion

Many people use vitamin E supplements worldwide as it acts as an antioxidant and is supposed to prevent...
cardiovascular risks; for example, 28%-30% of U.S. adults use supplements containing antioxidants such as vitamin E [6]. However, whether the antioxidant role of vitamin E is beneficial to prevent adverse cardiac outcomes or not is still controversial. Some studies support the thesis that the antioxidant role of vitamin E is beneficial in preventing cardiac disease and overall cardiac mortality [7-9]. However, some studies are against this thesis [10,11]. Thus, it is important to solve the question- Is the antioxidant property of vitamin E truly beneficial to protect CVD and CVD mortality?

Vitamin E as an Antioxidant

Alpha-tocopherol is a major isomer of vitamin E in vivo, which acts as an antioxidant by scavenging the free radicals of unsaturated lipids [31]. Lipid peroxidation, which has an important role in atherosclerosis and CVDs, has three stages; initiation, propagation, and termination [32]. Initially, carbon-centered lipid radical (alkyl radical) is produced from unsaturated lipid. This reaction is catalyzed by heat, light, and transition metals [32]. The alkyl radical then reacts with oxygen at a very high rate forming a peroxyl radical that can further attack another polysaturated lipid molecule propagating the chain reaction. The chain reaction continues until the peroxyl radical meets another radical and forms an inactive product (termination). Alpha-tocopherol transfers hydrogen atom to lipid-free radical (peroxyl, alkoxyl, and carbon-centered radical), giving rise to a non-radical lipid product and an alpha-tocopheroxy radical. The alpha-tocopheroxy radicals self-combine or react with other free radicals to form inactive products, thus, terminating the chain propagation. The summary of the major antioxidant property of alpha-tocopherol (a major isof orm of vitamin E) is depicted in Figure 2 [32].

FIGURE 2: Reaction Showing Peroxidation of Lipid and Vitamin E as an Antioxidant

LOO = lipid-peroxyl radical, LOOH = lipid hydroperoxide

Antioxidant Role of Vitamin E in Preventing CVD and CVD Mortality

A total of 25 studies were included in this review. Of 25 studies, 13 studies showed no association of vitamin E with CVDs. Zhao et al. 2017, a cohort study that included 134,358 participants, concluded that vitamin E is not associated with CVD mortality or total mortality in a long follow-up period of 8.2 years in males and 14.2 years in females; however, vitamin C and carotene were inversely associated with CVD mortality and overall mortality [19]. Similarly, Nagao et al., a case-control study involving 38,158 participants, showed no significant association between coronary heart disease and serum alpha- or gamma-tocopherol level [30]. Two studies were done in women only, Prentice et al. 2019 and Chae et al. 2012 [15, 33]. Both of these studies concluded that the role of vitamin E is not significant in preventing CVD and CVD mortality. However, Eshak et al. 2017, a cohort study involving 58,696 participants, showed that a higher intake of vitamin E was associated with a lower CVD mortality risk in females but not in men in the median follow-up period of 19.3 years [18].

Four studies included the male population only. Huang et al. 2019, a cohort study which included 29,133 men, showed the decreased cardiovascular mortality and overall mortality in participants with higher vitamin E level during 30 years of follow up [16]. Minotti et al. 2017, a cross-sectional study that included 615 males, concluded that higher serum vitamin E level was associated with decreased impaired flow-mediated dilation of the brachial artery [12]. Wannamethe et al. 2013, a cohort study including 3,919 men, showed that vitamin E is not significantly associated with decreased risk of heart failure [23]. Yildiran et al. 2011, a cross-sectional study including 66 men, concluded that lower serum vitamin E level is associated with congestive heart diseases [15]. The overall characteristics of the articles included in this review are shown in Table 4.

| Author        | Year | Location | Study type | Population | Results/Conclusion                                      |
|---------------|------|----------|------------|------------|---------------------------------------------------------|
| Prentice et   | 2019 | U.S.     | Cohort     | 3780 all   | No significant association of vitamin E in decreasing CVD risk. |
### Cardiovascular Outcome and All-Cause Mortality in Diabetic Hemodialysis

> Serum alpha-tocopherol level was not significantly associated with cardiovascular disease and supplementation of vitamin E was found. Higher intake of vitamin E or vitamin D, vitamin K was associated with lower cardiovascular mortality risk in women but not in men during the median follow up of 19.3 years.

### Vitamin E Intake and CVD/Mortality

- **Men with higher vitamin E status had significantly lower overall mortality and cause-specific mortality due to CVD found during 30 years of follow up independent of several other mortality risk factors.**

- **Increased dietary intake of vitamin E was significantly associated with decreased risk of long term cardiovascular outcome during 22 years of follow up in people with age 44.7 +/- 11.5 years.**

- **Higher intake of vitamin E or vitamin D, vitamin K was associated with lower cardiovascular mortality risk in women but not in men during the median follow up of 19.3 years.**

- **Significant improvement of vascular function following eight weeks of treatment with vitamin E in type 2 D.M. patients with hp2-2 gene who were of age >55 years.**

- **Vitamin E to the total intake of calories was inversely associated with impaired flow-mediated dilation (FMD) of the brachial artery. The impaired FMD is a marker of early arterial vascular dysfunction, which is an important feature of atherosclerosis.**

- **Total carotene and vitamin C level was inversely associated with CVD mortality and all-cause mortality; however, vitamin E was not associated with either of them during a long follow-up period (8.2 years for male, 14.2 years for female).**

- **Serum vitamin E level together with vitamin A, C, and D was significantly low in people aged 30 to 65 with metabolic syndrome.**

- **No clear association between vitamin E intake and CVD/mortality. No significant protective effect of vitamin E or vitamin C, beta carotene against CVD.**

- **Eight weeks supplementation of palm tocotrienol TRF-80 (420 mg/day tocotrienol+132 mg/day tocopherol) significantly increased the level of serum vitamin E; however, it did not significantly affect vascular endothelial function and other markers of CVD.**

- **No significant association of hypertension with the intake of vitamin E in people of age >40 years**

- **Higher vitamin E intake was associated with a low prevalence of HTN significantly in people of age >40 years**

- **Vitamin E was not associated significantly with day time or night time B.P. variation in Type2 D.M. patients of mean age 61.3 years.**

- **Lower cardiovascular mortality risk in women but not in men during the median follow up of 19.3 years.**

- **No significant association of hypertension with the intake of vitamin E in people of age >40 years.**

- **Lower intake of vitamin E or vitamin D, vitamin K was associated with an increased number of cardiovascular events such as myocardial infarction, ischemic stroke, and cardiovascular death in a patient with non-valvular atrial fibrillation.**

- **Serum vitamin C but not vitamin E was found to be significantly associated with the reduced risk of heart failure in men with or without preexisting MI.**

- **Serum alpha-tocopherol level was increased only in people with preexisting MI.**

- **Significant improvement of vascular function following eight weeks of treatment with vitamin E in type 2 D.M. patients with hp2-2 gene who were of age >55 years.**

### Table: Vitamin E Intake and CVD/Mortality

| Study                              | Year | Country | Study Design | Sample Size | Male (M) | Female (F) |
|------------------------------------|------|---------|--------------|-------------|---------|------------|
| Huang et al. [16]                  | 2019 | Finland | Cohort       | 29133       | M=51    | F=45%      |
| Lee et al. [17]                    | 2018 | China   | Cohort       | 875         | M=456   | F=419      |
| Eshak et al. [18]                  | 2017 | Japan   | Cohort       | 58696       | M=23099 | F=35597    |
| Alshiek et al. [34]                | 2017 | Israel  | RCT          | 20           | M=9     | F=11       |
| Minotti et al. [12]                | 2017 | Italy   | Cross-sectional | 615        | M=597   | F=11       |
| Zhao et al. [19]                   | 2017 | China   | Cohort       | 134358      | M=59739 |            |
| Godala et al. [27]                 | 2017 | Poland  | Case-control | 191         | M=101   | F=90       |
| Stepaniak et al. [20]              | 2016 | Russia, Poland, Czech | Cohort | 26993 | M=12642 | F=14351 |
| Stone house et al. [35]            | 2016 | South Australia | RCT | 87     | M=54    | F=33       |
| Llopis-González et al. [26]        | 2015 | Spain   | Case-control | 1514       | M=752   | F=762      |
| Kuwabara et al. [13]               | 2014 | Japan   | Cross-sectional | 3507      | M=1405  | F=2102     |
| Hodgson et al. [36]                | 2014 | Australia | RCT | 55     | M=41    | F=14       |
| Xu et al. [28]                     | 2014 | China   | Case-control | 60         | M=26    | F=34       |
| Cangemi et al. [21]                | 2013 | Italy   | Cohort       | 1012        | M=55%   | F=45%      |
| Wannamethe et al. [22]             | 2013 | U.K.    | Cohort       | 3919 All M  |         |            |
| Otero-Losada et al. [37]           | 2013 | Argentina | RCT | 112     | M=51    | F=61       |
| Espe et al.                         | 2013 | Germany | Cohort       | 1046        | M=565   |            |
Among 25 studies included in this review, most of the studies (i.e., 13 out of 25) failed to show any significant association regarding the role of vitamin E in preventing adverse cardiovascular outcomes. Twelve of them concluded that there is a significant association of vitamin E in preventing CVDs. Considering that a large number of participants were included in this review (360,840), it is worth noting that 12 studies, including only 95,741 participants, showed the association of vitamin E in preventing CVDs. To make it easier to interpret the data that we got in these twelve studies, studies including only 25.9% of participants compared to the total population in this review supported the association of vitamin E with CVD/mortality. Those studies were; five cohort studies, three case-control studies, three cross-sectional studies, and two randomized control trials.

From this study, we may conclude that vitamin E has no role in preventing CVDs. Thirteen out of twenty-five studies, including 267,099 participants, almost 75% of the total participants, rejected the hypothesis that vitamin E has a role in preventing CVD and cardiovascular mortality. This result tends to reject the hypothesis that vitamin E has a role in decreasing cardiovascular risks. According to Otero-Losada et al. 2015, even after supplementary vitamin E intake, serum vitamin E levels increased only in the participants who had lower than recommended initial vitamin E levels [37]. The studies that rejected the association between vitamin E and CVD were; six cohort studies, three case-control studies, and four randomized control trials. Some studies showed that higher vitamin E levels could increase myocardial infarction and stroke risk [29,30].

### Limitations

One of the possible limitations of this study includes the limited availability of review articles, case-control, and cohort studies. In addition, non-English papers and grey literature were excluded. Also, a full-text article, if not available, was excluded from this study. No appropriate nutrient data was available, and baseline circulating vitamin E was also unavailable in several studies. Furthermore, the result may have been affected by confounding factors in the studies included in this review, such as physical activity and alcohol intake.
Conclusions
We attempted to determine the protective role of vitamin E, if there is any, against the adverse cardiovascular outcomes in this paper. According to this review, we concluded that there is no significant correlation between vitamin E and cardiovascular risks. Most of the studies rejected the thesis that higher vitamin E intake helps prevent CVDs. Some studies even showed that higher serum vitamin E levels could be detrimental to health. Thus, vitamin E intake as a supplement to protect against CVDs is not a good practice. One should be more cautious while taking or prescribing vitamin E supplementation. In addition, a large-scale study is needed to be done to find out whether the high serum level of vitamin E is associated with adverse health outcomes or not.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. GBD 2016 Causes of Death Collaborators: Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017, 390:1151-210. 10.1016/S0140-6736(17)32152-9
2. GBD 2017 Causes of Death Collaborators: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392:1736-88. 10.1016/S0140-6736(18)32205-7
3. GBD 2017 DALYs and HALE Collaborators: Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392:1839-922. 10.1016/S0140-6736(18)32335-3
4. Lozano R, Naghavi M, Foreman K, et al.: Global and regional mortality from 235 causes of death in 1980 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380:2095-128. 10.1016/S0140-6736(12)61728-0
5. Clarke MW, Burnett JR, Croft KD: Vitamin E in human health and disease. Crit Rev Clin Lab Sci. 2008, 45:417-50. 10.1080/10408360802118625
6. Navah M, Anantharamiah GM, Reddy ST, et al.: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004, 45:995-1007. 10.1194/jlr.R400001-JLR200
7. Colombi ML: An update on vitamin E, tocopherol and tocotrienol-perspectives. Molecules. 2010, 15:2103-136. 10.3390/molecules15042103
8. Gahche J, Bailey R, Burt V, et al.: Dietary supplement use among U.S. adults has increased since NHANES III (1988-1994). NCHS Data Brief. 2011, 61:1-8.
9. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004, 45:995-1007. 10.1194/jlr.R400001-JLR200
10. Wright ME, Lawson KA, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, Albanes D: Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol Cancer Prevention Study. Am J Clin Nutr. 2006, 84:1200-7. 10.1093/ajcn/84.5.1200
11. Mezzetti A, Zuliani G, Romano F, Costantini F, Pierdomenico SD, Caccurutto F, Fellin R: Vitamin E and lipid peroxide plasma levels predict the risk of cardiovascular events in a group of healthy very old people. J Am Geriatr Soc. 2001, 49:535-7. 10.1046/j.1552-5415.2001.49110.x
12. Minotti GC, Cortese F, Corosello A, et al.: The influence of dietary components on early signs of atherosclerosis in apparently healthy young-adult males: an observational study of 615 subjects. Curr Vasc Pharmacol. 2017, 15:482-90. 10.2174/157016111566617021111809
13. Kuwabara A, Nakade M, Tamai H, Tsuboyama-Kasaoka N, Tanaka K: The association between vitamin E intake and hypertension: results from the re-analysis of the National Health and Nutrition Survey. J Nutr Sci Vitamino (Tokyo). 2014, 60:259-45. 10.3177/jnsv.60.239
14. Yildiran H, Mercanlilgil SM, Besler HT, Tokgözoglu L, Kepez A: Serum antioxidant vitamin levels in patients with coronary heart disease. Int J Vitam Nutr Res. 2011, 81:211-7. 10.1024/0300-9851/a000067
15. Prentice RL, Pettinger M, Neuhouser ML, et al.: Application of blood concentration biomarkers in nutritional epidemiology: example of carotenoid and tocopherol intake in relation to chronic disease risk. Am J Clin Nutr. 2019, 109:1189-96. 10.1093/ajcn/nzq560
16. Huang J, Weinstein SJ, Yu K, Männistö S, Albanes D: Relationship between serum alpha-tocopherol and overall and cause-specific mortality. Circ Res. 2019, 125:29-40. 10.1161/CIRCRESAHA.119.314944
17. Lee CH, Chan RSM, Wan HYL, et al.: Dietary intake of anti-oxidant vitamins A, C, and E is inversely associated with adverse cardiovascular outcomes in Chinese-A 22-years population-based prospective study. Nutrients. 2018, 10:1664. 10.3390/nu10111664
18. Enshah ES, Ito H, Yamagishi K, Cui R, Tamakoshi A: Dietary intakes of fat soluble vitamins as predictors of mortality from heart failure in a large prospective cohort study. Nutrition. 2018, 47:50-5.
